ArticleCancer research communications2024

Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.

Takafumi Koyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.